Teva Pharmaceutical Shares Surge Over 5.4% on Q2 Revenue and Full-Year Guidance Exceeding Expectations

Gelonghui July 31 | Teva Pharmaceutical Industries (TEVA.US) rose over 5.4%, trading at $17.3. In terms of news, Teva's Q2 revenue reached $4.16 billion, surpassing the market estimate of $4.05 billion; adjusted EBITDA was $1.17 billion, higher than the market estimate of $1.14 billion; adjusted earnings per share were $0.61. The company expects full-year revenue to be between $16 billion and $16.4 billion, compared to the market estimate of $16.01 billion; adjusted EBITDA is projected to be between $4.6 billion and $5 billion, versus the market estimate of $4.78 billion.